Slingshot members are tracking this event:

Merck (MRK) Announces Phase 3 Data Evaluating Letermovir in Clinically Significant Cytomegalovirus (CMV) Infection in CMV-Seropositive Adults Who Have Undergone an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Data Readout, Letermovir, Clinically Significant, Cytomegalovirus, Cmv-seropositive, Allogeneic Hematopoietic Stem Cell Transplant